AML Smacdown
Combination approach boosts new cancer therapy
An international research collaboration has found a means to improve the effect of mimetics of the second mitochondrial-derived activator of caspase (Smac), a novel class of targeted cancer drugs that act by inducing apoptotic cancer cell death and inhibiting pro-survival signaling.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.